Last reviewed · How we verify

NCT05372159: VMAP

Vanderbilt Memory and Aging Project

Recruiting now Last updated 6 August 2025
What this trial tests

trial testing none, observational study in Alzheimer Disease in 1,000 participants. Currently enrolling.

Timeline
17 September 2012
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorVanderbilt University Medical Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date17 September 2012
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Vanderbilt University Medical Center

Who can join

60 and older, any sex, with Alzheimer Disease or Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults. Adjusting for relevant clinical covariates, we will test the hypothesis that vascular health is associated with clinical, brain magnetic resonance imaging (MRI), neuropsychological, and cerebrospinal fluid markers of early cerebrovascular and Alzheimer's disease changes (i.e., prior to the onset of significant cognitive decline or dementia). Secondarily, we will examine medical and genetic factors that might mediate associations between vascular health and brain aging, such as inflammatory processes, insulin resistance, and genetic factors (e.g., APOE, a susceptibility risk factor for dementia). Findings will advance knowledge regarding the role that vascular health plays in brain aging.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Sphingolipid metabolism in brain insulin resistance and neurological diseases.
    Mei M, Liu M, Mei Y, Zhao J, et al · · 2023 · cited 29× · PMID 37867511 · DOI 10.3389/fendo.2023.1243132
  2. SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.
    Kuhn E, Klinger HM, Amariglio RE, Wagner M, et al · · 2025 · cited 7× · PMID 39985404 · DOI 10.1002/alz.14307

Verify or expand the search:

Other trials of none, observational study

Trials testing the same drug.

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05372159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing